Genetic variation in transforming growth factor-beta1 gene associated with increased risk of esophageal squamous cell carcinoma
Article first published online: 6 NOV 2007
DOI: 10.1111/j.1399-0039.2007.00935.x
2007 Blackwell Munksgaard
Additional Information
How to Cite
Wei, Y.-S., Xu, Q.-Q., Wang, C.-F., Pan, Y., Liang, F. and Long, X.-K. (2007), Genetic variation in transforming growth factor-beta1 gene associated with increased risk of esophageal squamous cell carcinoma. Tissue Antigens, 70: 464–469. doi: 10.1111/j.1399-0039.2007.00935.x
Publication History
- Issue published online: 6 NOV 2007
- Article first published online: 6 NOV 2007
- Received 15 March 2007; revised 2 June 2007, 3 August 2007, 24 August 2007; accepted 6 September 2007
- Abstract
- Article
- References
- Cited By
Keywords:
- ESCC;
- genetic alteration;
- polymorphism;
- TGF-β1
Abstract
The genetic alterations leading to esophageal squamous cell carcinoma (ESCC) are gradually being discovered. A wide variety of genes have been associated with ESCC development as well as tumor progression. Transforming growth factor-β1 (TGF-β1) is a multifunctional cytokine; it promotes tumor growth and metastasis in later stages of of cancer development. Variations in the DNA sequence in the TGF-β1 gene may lead to altered TGF-β1 production and/or activity, and so this can modulate an individual’s susceptibility to ESCC. To test this hypothesis, we investigated the association of the TGF-β1 gene −509 C/T and 869 T/C (Leu10Pro) polymorphisms and their haplotypes with the risk of ESCC. 247 patients with ESCC and 260 age- and sex-matched controls were studied using a polymerase chain reaction–restriction fragment length polymorphism. There were significant differences in the genotype and allele distribution of 869 T/C polymorphism of the TGF-β1 gene among cases and controls. The 869 TC and CC genotypes were associated with a significantly increased risk of ESCC as compared with the 869 TT genotypes [odds ratio (OR) = 1.882, 95% confidence interval (CI) 1.212–2.923, P = 0.005 and OR = 2.099, 95% CI 1.288–3.421, P = 0.003, respectively]. Consistent with the results of the genotyping analyses, the –509 T/869 C haplotype was associated with a significantly increased risk of ESCC as compared with the –509 C/869 T haplotype (OR = 1.463; 95% CI 1.120–1.912; P = 0.005). This study shows for the first time that TGF-β1 gene 869 T/C polymorphism may contribute to a genetic risk factor for ESCC in a Chinese population.

1399-0039/asset/TAN_centre.gif?v=1&s=9a80ec62fd17f78a0249f1b93be90b118a9517ba)
1399-0039/asset/TAN_right.gif?v=1&s=39a7ec08c038d2c61e6d1f9b79bf9a257623548c)
